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Aim To determine if preoperative treatment with a topical 
non-steroidal anti-inflammatory drug (NSAID) lowers the con-
centration of intraocular interleukin (IL)-12 and the incidence 
of postoperative macular edema in patients with non-prolifer-
ative diabetic retinopathy undergoing cataract surgery.
Methods A total of 55 patients were randomized to diclofen-
ac (n = 27) or placebo (n = 28). Patients receiving diclofenac 
started preoperative treatment with 0.1% topical diclofenac 
four times a day 7 days before cataract surgery and the ther-
apy was discontinued 30 days after surgery. Patients in the 
control group were administered placebo 7 days preopera-
tively and a standard postoperative therapy with 0.1% topical 
dexamethasone four times a day for 30 days after surgery. All 
patients received postoperative antibiotic prophylaxis with 
tobramycin eye drops four times daily for 30 days. Seven days 
before the cataract surgery, on the day of surgery, and 1, 7, 
30, and 90 days after surgery, central foveal thickness (CFT) 
was measured with optical coherence tomography (OCT) 
and the aqueous humor was sampled at the beginning of 
cataract surgery for the analysis of IL-12 concentration. Due 
to loss to follow-up and insufficient aqueous humor samples, 
the data of 3 patients treated with diclofenac and 8 patients 
receiving placebo were not analyzed.
Results The aqueous humor IL-12 concentration was sig-
nificantly lower in the diclofenac group than in the placebo 
group (t = −2.85, p = 0.007). The diclofenac group had a sig-
nificantly smaller increase in CFT after phacoemulsification 
(F = 13.57, p<0.001).
Conclusion Patients preoperatively treated with diclofenac 
had significantly lower intraocular levels of IL-12 and a lower 
increase in CFT, which indicates that a combination of pre-
operative and postoperative treatment with a topical NSAID 
may lower the incidence of postoperative macular edema in 
patients with diabetic retinopathy.
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In the USA alone, approximately 29,1 million people (9.3% 
of the population) suffer from diabetes mellitus (1). The 
prevalence of diabetes mellitus in Croatia is 6.1% in the 18-
64-year age group (2)..It is estimated that diabetic retinop-
athy, one of major diabetes complications, is among the 
leading causes of vision loss in adults aged 20–74 years (3). 
Diabetes also accelerates the formation of visually signifi-
cant cataracts (4), and diabetic patients often benefit from 
cataract surgery in both eyes (5). However, several stud-
ies have suggested that cataract surgery, which is usually 
a definitive treatment for this type of visual impairment, 
worsens the underlying diabetic retinopathy and macular 
edema (6,7). The leakage of the intravascular contents from 
dilated perifoveal capillaries initially causes thickening of 
the macula (edema formation), which may over time prog-
ress to cystoid space formation within the outer plexiform 
layer and inner nuclear layer of the retina, leading to cys-
toid macula edema (CME) (8). Several authors have found 
significantly increased intraocular concentrations of proin-
flammatory interleukins IL-6, IL-8, and IL-12 in patients with 
diabetes compared with patients without diabetes (9-11). 
IL-12 plays an important role in the enhancement of the 
cytotoxic activity of NK cells and CD8+ cytotoxic and T-
lymphocytes (11). IL-12 is secreted by human dendritic 
cells and macrophages in response to various signals as-
sociated with defense and wound healing (11). Involve-
ment of proinflammatory interleukins indicates that some 
patients with diabetic retinopathy have a subclinical in-
traocular inflammation. Patients with diabetes undergoing 
phacoemulsification cataract surgery seem to have a dou-
bling of diabetic retinopathy progression rates 12 months 
after surgery (12). A significant thickening of the retina in 
the macular region was found in a recent study comparing 
the postoperative changes in central foveal thickness (CFT) 
measured by optical coherence tomography (OCT) in pa-
tients with diabetes and healthy subjects treated for cat-
aracts (13). Modern cataract surgical techniques, charac-
terized by small incisions and short operating times, have 
little influence on the progression of diabetic retinopathy, 
except on developing macular edema (14). Despite ad-
vances in cataract surgery, cystoid macular edema is still 
recognized as one of the most common causes of poor 
visual outcome following cataract surgery (15).
Two types of compounds are available for topical use to re-
duce the risk of CME after cataract surgery: corticosteroids 
and nonsteroidal anti-inflammatory drugs (NSAIDs). Corti-
costeroids are effective in suppressing postoperative in-
flammation, but have little suppression effects on CME 
and potentially increase intraocular pressure. Sever-
al trials in the effectiveness of NSAIDs in the treatment of 
CME following cataract surgery showed positive effect of 
NSAID-s on postoperative macular edema (16-19). A few 
studies investigated that effect in patients that started 
NSAID therapy preoperatively (20,21), and we found only 
one study in adult diabetic patients with non-proliferative 
diabetic retinopathy requiring cataract surgery that in-
stilled NSAID therapy before surgery (22).
Diclofenac inhibits cyclooxygenase, an enzyme essential in 
the biosynthesis of prostaglandins. It is indicated for the 
treatment of postoperative inflammation in patients who 
have undergone cataract extraction and for the temporary 
relief of pain and photophobia in patients undergoing cor-
neal refractive surgery.
We reviewed the available literature and found that, in pa-
tients with diabetes, the efficacy of both preoperative and 
postoperative topical diclofenac administration aimed at 
postoperative macular edema incidence reduction has 
not been explored. Additionally, quantitative analysis of 
postoperative CME with cataract surgery in patients pre-
operatively treated with topical diclofenac has not been 
studied. Therefore, our aim was to examine the effect of 
preoperative topical diclofenac treatment on lowering in-
traocular IL-12 concentration and macular edema forma-
tion following phacoemulsification in patients with dia-
betic retinopathy.
PATIENTS AND METHODS
The prospective, double-blind, randomized placebo-con-
trolled clinical trial was performed between January 2013 
and December 2014 in collaboration between the Eye 
Clinic Medić Jukić, Split, Croatia, and the Clinical Hospital 
Center Split, Croatia, in accordance with the Declaration 
of Helsinki. Patients included in this study received both 
written and oral information about the study protocol and 
signed a written informed consent.
Patients
Between January 2013 and June 2014, 107 diabetic pa-
tients referred for cataract surgery were assessed for eligi-
bility (Figure 1). Inclusion criteria were age over 60 years, 
presence of mild and moderate diabetic retinopathy clas-
sified in accordance with Early Treatment Diabetic Retin-
opathy Study (23), and presence of cataracts graded ac-
cording to the Lens Opacities Classification System, version 
III (LOCS III) as grade 2-3 (24). We did not include patients 
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with other chronic or acute eye diseases (uveitis, central 
or branch retinal vein occlusion, or presence of epiretinal 
membrane), previous laser photocoagulation, and hyper-
sensitivity to any component of the diclofenac eye drops, 
and those on oral anticoagulant therapy or allergic to sali-
cylates.
Patients with diabetic retinopathy included in the study 
were randomized using sealed envelopes into either the 
experimental group receiving topical diclofenac or the 
control group receiving placebo. Topical treatment was 
prepared in unlabeled bottles, so that the patients and all 
examiners were blinded for the type of treatment applied.
Methods
Patients who met all inclusion criteria were invited to par-
ticipate in the study and were examined at one study site. 
At the initial visit, the patients signed informed consent 
form and underwent a complete ophthalmologic exami-
nation performed by a single examiner.
Complete eye examination included best corrected visual 
acuity, Goldmann applanation tonometry, slit lamp biomi-
croscopy of the anterior eye segment, binocular indirect 
slit lamp fundoscopy, fundus photography, and spectral 
OCT of the macular area (SOCT Copernicus, OPTPOL Tech-
nology, Zawiercie, Poland). Ophthalmologic examination 
was performed 7 days before the cataract surgery, on the 
day of surgery, and on days 1, 7, 30, and 90 after surgery.
In the experimental group, patients started the preoper-
ative treatment with 0.1% topical diclofenac four times a 
day (Naclof, Exelsion, France) 7 days before the cataract 
surgery, and the therapy was discontinued 30 days after 
surgery. In the control group, patients were administered 
placebo 7 days preoperatively and the standard postoper-
ative therapy with 0.1% topical dexamethasone (Maxidex 
Alcon, USA) four times a day for 30 days after surgery. All 
patients received postoperative antibiotic prophylaxis with 
tobramycin eye drops (Tobrex, Alcon, USA) administered 
four times daily for 30 days. Upon the start of cataract sur-
gery, 0.2 mL of the aqueous humor was taken for IL-12 con-
FIgurE 1. Flow diagram of patients included in the study.
CLINICAL SCIENCE52 Croat Med J. 2017;58:49-55
www.cmj.hr
centration measurements by enzyme-linked immunosor-
bent assay using an EASIA ELISA kit (KAC1561, BioSource 
Inc., USA). Quantitative analysis of IL-12 was performed at 
the Department for Medical Laboratory Diagnostics of the 
Split University Hospital Center, Split, Croatia. Cataract sur-
gery was done with phacoemulsification (Alcon Infinity 
Phaco Machine, Alcon Inc., Hünenberg, Switzerland).
Statistical analysis
Descriptive and inferential statistical analyses were per-
formed. The parameters for diabetes duration and IL-12 
concentration were expressed as arithmetic mean with 
standard deviation (mean±SD), and for phacoemulsifi-
cation time, diabetes duration, and age as median with 
range. Frequencies were used in the description of the 
clinical profile (CME and worsening of diabetic retinopa-
thy). Student’s t-test was used to test the mean difference 
between groups for IL-12 concentrations and phacoemul-
sification time, χ2 test was used to test the differences in 
cystoid macular edema frequency, and ANOVA for repeat-
ed measurements was used to analyze central foveal thick-
ness change during follow-up visits. The difference in con-
centrations of IL-12 in the aqueous humor was examined 
with the unpaired t-test. The correlation of preoperative 
intraocular inflammation (IL-12 concentration in the aque-
ous humor) and postoperative changes in the CFT was ex-
amined with Pearson correlation analysis and at each time 
point separately (0, 1, 7, 30, and 90 days postoperatively). 
Normal distribution of the data was checked by Kolmog-
orov-Smirnoff test. For all tests, the significance level was 
set at p = 0.05. The study was powered enough to detect 
a mean difference in IL-12 concentrations of 33.2 pg/mL 
between the groups, under the assumptions of SD in the 
experimental and control groups of 26.5 and 29.9, respec-
tively, two-sided significance level of 0.05, power of 80%, 
and at least 14 patients allocated in experimantal and 12 in 
the control group. Data were analyzed with SPSS 13.0 soft-
ware (SPSS Inc., Chicago, Illinois, USA).
rESuLTS
This study included 55 patients with type 2 diabetes (28 
men, 27 women), with a mean age of 64.5 ± 17.5 years and 
a mean diabetes duration of 20 ± 15 years (Table 1). The ex-
perimental and control groups did not differ significantly 
according to age, sex, and the time from diagnosis of di-
abetes. Due to patient loss-to-follow-up and insufficient 
aqueous humor samples, the data of 3 patients in the ex-
perimental group receiving diclofenac and 8 patients in the 
TAbLE 1. Demographic characteristics, duration of diabetes, and the duration of the phacoemulsification time in patients with dia-
betic retinopathy receiving diclofenac and placebo
No. (%) of patients
Characteristics diclofenac group (n = 27) placebo group (n = 28) p*
Age (median, range; years) 73 (59–81) 70 (47–82)
Sex
women 13 (48.1) 14 (50.0)
men 14 (51.9) 14 (50.0)
Duration of diabetes (median, range; years) 18.9 (5.0-35.0) 16.7 (10.0-28.0) 0.420
Phacoemulsification time (median, range; cde†) 16.6 (5.8-50.1) 15.3 (2.2-50.1) 0.630
*Student’s t-test.
†cde - cumulative dissipated energy.
FIgurE 2. Correlation between interleukin (IL)-12 concentra-
tions in humor aqueous and the change of central foveal 
thickness (CFT) between day 7 before surgery and the day of 
surgery when the aqueous humor was sampled in patients 
receiving diclofenac (circles) and placebo (squares).
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control group receiving placebo were not analyzed (Figure 
1). The aqueous humor IL-12 concentration, as an indicator 
of intraocular inflammation, was significantly lower in the 
experimental group (33.4 ± 26.5 pg/mL) treated preopera-
tively with diclofenac than in the control group receiving 
placebo (57.7 ± 29.9 pg/mL; t = –2.85, p = 0.007). There was 
no significant correlation between the CFT change and the 
IL-12 concentration in the aqueous humor on the day of 
the surgery in either group (Figure 2). Patients in the ex-
perimental group had a significantly smaller increase in 
CFT after phacoemulsification compared to patients in the 
control group (F = 13.57, p<0.001; Figure 3). In the exper-
imental group, the peak of change in CFT was recorded 
at day 30 after surgery with subsequent decrease toward 
the day 90 postoperatively. In the control group, the CFT 
change progressively increased peaking on day 90 after 
surgery. The phacoemulsification time in the control and 
experimental groups did not differ significantly (Table 1). 
During the follow-up period, the OCT scans showed cys-
toid macular edema (CME) in 10 (37%) patients in experi-
mental group and 12 (43%) patients in the control group 
(χ2 test = 87, p = 0.87).
DISCuSSION
We found that preoperative treatment with diclofenac sig-
nificantly decreased the aqueous humor IL-12 concentra-
tion and preoperative intraocular inflammation due to dia-
betic retinopathy and, consequently, reduced the amount 
of postoperative macular edema caused by phacoemulsi-
fication. To the best of our knowledge, this is the first study 
investigating this effect of an ophthalmic NSAID.
Growing evidence shows that immunological reactions 
play a major role in the pathogenesis of diabetic retinopa-
thy and that many inflammation mediators may be found 
in the vitreous body and aqueous humor (9-11). Thus, pa-
tients with diabetic retinopathy usually have a subclinical 
degree of intraocular inflammation, which may worsen the 
inflammation in cases where cataract surgery is needed. 
Previous research on postoperative macular edema has fo-
cused on its relation to operative manipulation and other 
possible pathophysiologic mechanisms. However, despite 
the many studies available, few have addressed the issue 
of a significantly greater incidence of postoperative macu-
lar edema in patients with diabetic retinopathy (14). An-
alyzing the systematic reviews by Wielders et al (25) and 
Kessel et al (26) on comparing the effect of topical steroids 
with topical NSAIDs in controlling inflammation and pre-
venting macular edema after cataract surgery in patients 
with diabetic retinopathy, we found seven trials reporting 
that the combination of topical corticosteroids and topical 
NSAIDs reduced the odds of developing macular edema 
after cataract surgery as compared to topical corticoster-
oids as a single-drug treatment. We found only one trial 
comparing NSAIDs and corticosteroids as a single-drug 
treatment in patients with non-proliferative diabetic retin-
opathy, but without preoperative administration of NSAIDs 
(16). We found two studies comparing NSAIDs started 1 to 
3 days before surgery vs on the day of surgery or day after, 
but unlike our study, these studies enrolled only non-dia-
betic patients and found that preoperative administration 
of ketorolac and diclofenac were significantly more effec-
tive in controlling inflammation than if the drug adminis-
tration was started on the day of surgery (20,27). Singh et 
al (22) evaluated preoperative and postoperative NSAID 
(nepafenac) ophthalmic solution in the prevention of mac-
ular edema following cataract surgery in diabetic retinopa-
thy patients and found significantly lower percentage of 
patients in the nepafenac group that developed macular 
edema relative to patients in the sham group.
Pseudophakic cystoid macular edema was 6 to 7 times 
more prevalent in patients randomized to topical steroids 
compared with topical NSAIDs when evaluated by fluo-
rescein angiography or OCT at 4 to 5 weeks after cata-
ract surgery (26). Shimura et al (19) and Ching et al (28) 
found that macular thickness assessed by OCT peaks 
FIgurE 3. Mean change of the central foveal thickness (CFT) 
in the experimental group treated with diclofenac for 7 days 
before surgery (full bars) and the control group receiving 
placebo (empty bars). The change was calculated as the dif-
ference in CFT between baseline measurement 7 days before 
the phacoemulsification and each control visit on the day of 
surgery (day 0) and 1, 7, 30, and 90 days after surgery. boxes 
and whiskers represent mean valued and standard deviations.
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at approximately 4 to 8 weeks postoperatively. In our study, 
CFT peaked in the experimental group at 4 weeks after sur-
gery, with subsequent gradual decrease toward the week 
12 after surgery, and in the control group, CFT was progres-
sively increasing and peaked at week 12 after surgery, what 
could be explained by different study populations accord-
ing to diabetic status.
Singh et al (22) evaluated preoperative and postoperative 
NSAID (nepafenac) ophthalmic solution in the prevention 
of macular edema following cataract surgery in diabetic 
retinopathy patients and they found significantly lower 
percentage of patients in the nepafenac group who de-
veloped macular edema relative to patients in the sham 
group. Our results also showed that patients treated pre-
operatively and postoperatively with diclofenac 7 days be-
fore phacoemulsification had significantly lower increase 
in CFT, which suggests that preoperative administration 
of topical NSAIDs lowers the incidence of postoperative 
macular edema in patients with diabetic retinopathy. We 
have also found lower intraocular IL-12 concentration in 
diclofenac-treated group, which suggests that intraocu-
lar inflammation may play a significant role in the macular 
edema formation.
We found no significant correlation between IL-12 concen-
tration in the aqueous humor and CFT change in the 7-day 
period before the surgery. One reason may be that the en-
rolled patients had already had a diabetic retinopathy with 
consequent macular edema to a different extent. Howev-
er, IL-12 is not the only inflammatory mediator involved in 
macular edema formation and further research should ad-
dress this issue.
The main limitation of this study is the possibly short fol-
low-up time, because our resulted showed that CFT was 
increasing in the control group up to the last follow-up 
visit, which was 90 days after the surgery. From our clinical 
experience, optimal follow-up time would be 12 months, 
because macular edema after cataract surgery can persist 
up to one year. Further research should focus on investigat-
ing the effectiveness of preoperative NSAID therapy in the 
treatment and prevention of postoperative macular edema 
on a larger number of patients with diabetic retinopathy.
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